Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion vs Fluoxetine for Depression in ESRD
NCT02238977Phase 4Terminated
- Sponsor
- University of Arkansas
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupropion in major depressive disorder (MDD), sponsored by University of Arkansas. Primary endpoint: Hamilton Depression Rating Scale at 12 weeks. Started Mar 2016; status: terminated.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02238977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238977.